Neuronetics Reports Second Quarter 2018 Financial and Operating Results

8/14/18

MALVERN, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the second quarter ended June 30, 2018.

  • Second quarter 2018 revenue of $13.3 million, an increase of 29% over the second quarter of 2017
  • Second quarter 2018 U.S. treatment session revenue of $8.9 million, an increase of 21% over the second quarter of 2017
  • Second quarter 2018 U.S. NeuroStar® Advanced Therapy revenue of $3.6 million, an increase of 42% over the second quarter of 2017

“We are very proud of our accomplishments during the second quarter of 2018, not only in terms of the growth in new NeuroStar Advanced Therapy Systems and treatment sessions, but also achieving other key milestones we established to attain our goals in 2018 and beyond,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics. “Standard drug therapy for depression continues to fail for a significant portion of patients suffering with depression. In 2018, we will continue to focus on expanding NeuroStar to new providers while at the same time increasing system utilization within our existing practices to allow clinicians to provide a safe, effective non-drug TMS treatment to patients that have not had success with antidepressant drug therapy.”

Second Quarter Financial and Operating Results

Total revenue for the second quarter of 2018 was $13.3 million, representing 29% growth over second quarter of 2017 revenue of $10.3 million. U.S. revenue for the second quarter of $12.9 million increased 26% over the second quarter of 2017 revenue of $10.2 million.

U.S. NeuroStar Advanced Therapy Revenue for the second quarter of 2018 was $3.6 million, an increase of 42% over second quarter 2017 revenue of $2.5 million. The increase in U.S. NeuroStar revenue was primarily a result of 44% higher unit volume driven by our ongoing sales force expansion and marketing initiatives offset by a 2% decline in average selling prices as compared to the prior year period. Included in the U.S. NeuroStar Advanced Therapy Revenue was a multi-unit order of $0.5 million.

As of June 30, 2018, the active unit installed base in the U.S. was 816. This represents an increase of 126 units over the active unit installed base as of June 30, 2017, and an increase of 35 units over the active installed base as of March 31, 2018.

U.S. Treatment Session revenue for the second quarter of 2018 was $8.9 million, an increase of 21% over second quarter of 2017 revenue of $7.4 million. The increase in U.S. Treatment Session revenue was primarily the result of a 25% increase in the number of treatment sessions performed. This increase was partially offset by a 4% decline in average selling price due to certain volume pricing discounts within our existing customer base.

Gross margin for the second quarter of 2018 was 75.5%, which was consistent to the second quarter of 2017 gross margin of 75.7%.

Operating expenses during the second quarter of 2018 were $15.2 million, an increase of $4.9 million compared to $10.4 million in the second quarter of 2017. The increase was primarily driven by sales force expansion, marketing initiatives, as well as additional general and administrative expenses incurred in preparation for our current status as a public company.

Net loss for the second quarter of 2018 was $7.5 million, or $30.60 per share, as compared to second quarter 2017 net loss of $2.9 million, or $16.58 per share. Weighted-average common shares outstanding for the three and six months ended June 30, 2018 does not include either 11.0 million shares of common stock issued upon the conversion of convertible preferred stock or 6.325 million shares of common stock issued upon the closing of our initial public offering, both of which occurred on July 2, 2018.

EBITDA for the second quarter of 2018 was $(6.3) million as compared to the second quarter of 2017 EBITDA of $(2.0) million. EBITDA includes $0.2 million of share-based compensation expense for the three months ended June 30, 2018 and 2017, respectively. EBITDA for the second quarter of 2018 also includes a $1.4 million charge for the revaluation of the Company’s convertible preferred stock warrant liability. Refer to the accompanying financial table for a reconciliation of EBITDA, which is a non-GAAP measure, to net loss.

Cash and cash equivalents were $14.5 million as of June 30, 2018. This compares to cash and cash equivalents of $20.4 million as of March 31, 2018. The cash balance as of June 30, 2018 does not include net proceeds (after underwriter and other company costs) from the closing of the Company’s initial public offering on July 2, 2018 of approximately $97.5 million.

Business Outlook

For the full year 2018, the Company expects to report revenue of between $50.0 and $51.5 million, representing 24% - 27% year-over-year growth, respectively.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA. NeuroStar Advanced TMS Therapy is indicated for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.